Ipsen completes purchase of all of OBI-1 assets from Octagen Corporation

This article or press release has no online content. Please download the associated documents for more information.

Associated Documents

20080717_closing_octagen1.pdf

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023